Relapsed or Refractory Multiple Myeloma Clinical Trials

168 clinical trials for Relapsed or Refractory Multiple Myeloma across international registries, including 57 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma — RECRUITING · PHASE1
• A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) — RECRUITING · PHASE1
• A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) — RECRUITING · PHASE3
• A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma — RECRUITING · PHASE1
• A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) — RECRUITING · PHASE3
• In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma — RECRUITING · PHASE1
• A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis — RECRUITING · PHASE1
• Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma — RECRUITING · PHASE2
• A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma — RECRUITING · PHASE3
• A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma — RECRUITING · PHASE3
• A study to characterize the safety, efficacy, pharmacokinetics of subcutaneous administration of Etentamig (ABBV-383) in patients with relapsed or refractory Multiple Myeloma — RECRUITING · PHASE1
• Study to evaluate the safety, tolerability, maximum tolerated dose and clinical activity of TNB-383B when given to patients with multiple myeloma — RECRUITING · PHASE1
• A PHASE 3 RANDOMIZED STUDY COMPARING JNJ-79635322 AND AN ANTI-BCMAXCD3 BISPECIFIC ANTIBODY IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 3 PRIOR LINES OF THERAPY INCLUDING A PI, AN IMID, AND AN ANTI-CD38 ANTIBODY — RECRUITING · PHASE3
• A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma — RECRUITING · PHASE1
• Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma — RECRUITING · PHASE1
• A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma — RECRUITING · PHASE2
• A PHASE III OPEN-LABEL, RANDOMISED, MULTICENTRE STUDY COMPARING AZD0120, A DUAL-TARGETING AUTOLOGOUS CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY DIRECTED AGAINST BCMA AND CD19, VERSUS STANDARD REGIMENS IN PARTICIP WITH RELAPSED REFRACTORY MULTIPLE MYELOMA (DURGA-4) — RECRUITING · PHASE3
• Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration — RECRUITING · PHASE1
• Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration — RECRUITING · PHASE1
• Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma — RECRUITING · PHASE1
• YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma — RECRUITING · PHASE1
• A PHASE 1B/2A, MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND SCHEDULE, AND EVALUATE THE SAFETY AND PRELIMINARY EFFICACY OF MEZIGDOMIDE IN COMBINATION WITH ELRANATAMAB IN PARTICIPANTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA — RECRUITING · PHASE1
• Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma — RECRUITING · NA
• Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma — RECRUITING · PHASE1
• A PHASE 1/2 STUDY OF ETENTAMIG IN COMBINATION WITH A CELMOD AGENT FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA — RECRUITING · PHASE1
• A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO COMPARE THE EFFICACY AND SAFETY OF ANITOCABTAGENE AUTOLEUCEL VERSUS STANDARD OF CARE THERAPY IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA — RECRUITING · PHASE3
• A FIRST-IN-HUMAN, OPEN-LABEL, PHASE 1 STUDY TO EVALUATE THE SAFETY, ANTITUMOR ACTIVITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SUBCUTANEOUS SAR446523, AN ANTI GPRC5D ADCC-ENHANCED MONOCLONAL ANTIBODY, IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA — RECRUITING · PHASE1
• A PHASE 2, OPEN-LABEL, MULTICENTER STUDY OF BMS-986393, A GPRC5D-DIRECTED CAR T CELL THERAPY IN ADULT PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (QUINTESSENTIAL) — RECRUITING · PHASE2
• A STUDY OF ELRANATAMAB MANAGEMENT WITH OUTPATIENT AND INTERMITTENT DOSING IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: EMBRACE TRIAL — RECRUITING
• A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma. — RECRUITING · PHASE1
• A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF ABBV-383 COMPARED WITH STANDARD AVAILABLE THERAPIES IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (3L+ RRMM MONOTHERAPY STUDY) — RECRUITING · PHASE3
• A PHASE 1,MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND PRELIMINARY EFFICACY OF BMS-986393 IN NOVEL COMBINATIONS IN PARTICIPANTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA AND DETERMINE THE RECOMMENDED DOSE FOR EACH ADD-ON INVESTIGATIONAL COMPONENT — RECRUITING · PHASE1
• A MODULAR PHASE I/II, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, IMMUNOGENICITY, PHARMACODYNAMICS, AND PRELIMINARY EFFICACY OF AZD0305 AS MONOTHERAPY OR IN COMBINATION WITH ANTICANCER AGENT(S) IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA — RECRUITING · PHASE1
• A PHASE 1 RANDOMIZED, OPEN-LABEL PHARMACOKINETIC COMPARABILITY STUDY COMPARING PRE- AND POST-CHANGE TECLISTAMAB IN PARTICIPANTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA — RECRUITING · PHASE1
• MAGNETISMM-32 A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB, POMALIDOMIDE, DEXAMETHASONE (EPD) OR POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE (PVD) OR CARFILZOMIB, DEXAMETHASONE (KD) IN PARTICIPANTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTI-CD38 DIRECTED THERAPY — RECRUITING · PHASE3
• A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALNUCTAMAB COMPARED TO STANDARD OF CARE REGIMENS IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) — RECRUITING · PHASE3
• A PHASE 3 RANDOMIZED STUDY COMPARING TALQUETAMAB IN COMBINATION WITH POMALIDOMIDE (TAL-P), TALQUETAMAB IN COMBINATION WITH TECLISTAMAB (TAL-TEC), AND INVESTIGATOR¿S CHOICE OF EITHER ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD) OR POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE (PVD) IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MYELOMA WHO HAVE RECEIVED 1 TO 4 PRIOR LINES OF THERAPY INCLUDING AN ANTI-CD38 ANTIBODY AND LENALIDOMIDE — RECRUITING · PHASE3
• A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH IBERDOMIDE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA — RECRUITING · PHASE1
• AN OPEN-LABEL, RANDOMIZED PHASE IB/II STUDY EVALUATING SAFETY, TOLERABILITY, AND CLINICAL ACTIVITY OF FORIMTAMIG-BASED TREATMENT COMBINATIONS IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA — RECRUITING · PHASE1
• AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTIBCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) — RECRUITING · PHASE3
• A MULTICENTER, PHASE 1B, OPEN-LABEL STUDY TO EVALUATE DOSE OPTIMIZATION MEASURES AND SAFETY OF ABBV-383 IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA — RECRUITING · PHASE1
• A PHASE 3 RANDOMIZED STUDY COMPARING TECLISTAMAB MONOTHERAPY VERSUS POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE (PVD) OR CARFILZOMIB, DEXAMETHASONE (KD) IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED 1 TO 3 PRIOR LINES OF THERAPY, INCLUDING AN ANTI-CD38 MONOCLONAL ANTIBODY AND LENALIDOMIDE — RECRUITING · PHASE3
• A PHASE 1 STUDY OF KTX-1001, AN ORAL, FIRST-IN-CLASS, SELECTIVE, AND POTENT MMSET CATALYTIC INHIBITOR THAT SUPPRESSES H3K36ME2 IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA, AMENDMENT 1.0 DATED 15 JULY 2022 — RECRUITING · PHASE1
• A RANDOMIZED, PHASE 3, OPEN LABEL STUDY EVALUATING SUBCUTANEOUS VERSUS INTRAVENOUS ADMINISTRATION OF ISATUXIMAB IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM) — RECRUITING · PHASE3
• A PHASE 1/2 OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND IMMUNOGENICITY OF MODAKAFUSP ALFA (TAK-573) AS A SINGLE AGENT IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA — RECRUITING · PHASE1
• A PHASE 1B/2 DOSE-ESCALATION AND COHORT-EXPANSION STUDY TO DETERMINE THE SAFETY AND EFFICACY OF BGB-11417 AS MONOTHERAPY, IN COMBINATION WITH DEXAMETHASONE, DEXAMETHASONE/CARFILZOMIB, DEXAMETHASONE/DARATUMUMAB, AND DEXAMETHASONE/POMALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND T(11;14) — RECRUITING · PHASE1
• AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB+DARATUMUMAB VERSUS DARATUMUMAB+POMALIDOMIDE+DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR — RECRUITING · PHASE3
• A PHASE 3 RANDOMIZED STUDY COMPARING TECLISTAMAB IN COMBINATION WITH DARATUMUMAB SC (TEC-DARA) VERSUS DARATUMUMAB SC, POMALIDOMIDE, AND DEXAMETHASONE (DPD) OR DARATUMUMAB SC, BORTEZOMIB, AND DEXAMETHASONE (DVD) IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA — RECRUITING · PHASE3
• A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING IBERDOMIDE, DARATUMUMAB AND DEXAMETHASONE (IBERDD) VERSUS DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (DVD) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) — RECRUITING · PHASE3
• AN OPEN-LABEL, MULTICENTER, PHASE I TRIAL EVALUATING THE SAFETY AND PHARMACOKINETICS OF ESCALATING DOSES OF BFCR4350A IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA — RECRUITING · PHASE1

Refine this search